Induction of human cytomegalovirus (HCMV)-glycoprotein B (gB)-specific neutralizing antibody and phosphoprotein 65 (pp65)-specific cytotoxic T lymphocyte responses by naked DNA immunization

Vaccine

Volumn 17, Issue 1, 1999, Pages 50-58

  Endresz, Valeria ^a,b   Kari, Laszlo ^a   Berencsi, Klara ^a   Kari, Csaba ^a   Gyulai, Zsofia ^a   Jeney, Csaba ^a   Pincus, Steve ^c   Rodeck, Ulrich ^a   Méric, Claude ^d   Plotkin, Stanley A ^d   Gönczöl, Eva ^a,b  

^a WISTAR INSTITUTE   (United States)

^b UNIVERSITY OF SZEGED   (Hungary)

^c Virogenetics Corporation   (United States)

^d 1541 Avenue Marcel Merieux 69280 ^*  (France)

Author keywords

Antibody; CTL; DNA immunization; HCMV

Indexed keywords

CYTOMEGALOVIRUS ANTIBODY; CYTOMEGALOVIRUS VACCINE; DNA VACCINE; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; NEUTRALIZING ANTIBODY; PLASMID DNA; VIRUS GLYCOPROTEIN; VIRUS PHOSPHOPROTEIN;

ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ARTICLE; CYTOMEGALOVIRUS INFECTION; CYTOTOXIC T LYMPHOCYTE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN CYTOMEGALOVIRUS; IMMUNIZATION; INTRAMUSCULAR DRUG ADMINISTRATION; MOUSE; NONHUMAN; PLASMID; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES, VIRAL; ANTIBODY SPECIFICITY; CYTOMEGALOVIRUS; CYTOTOXICITY, IMMUNOLOGIC; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN ISOTYPES; LYMPHOCYTE ACTIVATION; MEMBRANES; MICE; MICE, INBRED BALB C; NEUTRALIZATION TESTS; PHOSPHOPROTEINS; PLASMIDS; T-LYMPHOCYTES, CYTOTOXIC; VACCINES, DNA; VIRAL ENVELOPE PROTEINS; VIRAL MATRIX PROTEINS;

EID: 0032889364     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(98)00145-5     Document Type: Article

References (60)

1. Donnelly J.J., Friedman A., Martinez D.L.et al. Preclinical efficacy of a prototype DNA vaccine: enhanced protection against antigenic drift in influenza virus. Nature Med. 1:1995;583-587.
2. Fynan E.F., Webster R.G., Fuller D.H., Haynes J.R., Santoro J.C., Robinson H.L. DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations. Proc. Natl. Acad. Sci. USA. 90:1993;11478-11482.
3. Raz E., Carson D.A., Parker S.E.et al. Intradermal gene immunization: the possible role of DNA uptake in the induction of cellular immunity- to viruses. Proc. Natl. Acad. Sci. USA. 91:1994;9519-9523.
4. Robinson H.L., Hunt L.A., Webster R.G. Protection against a lethal influenza virus challenge by immunization with a hemagglutinin-expressing plasmid DNA. Vaccine. 11:1993;957-960.
5. Robinson, HL, Feltquate, DM, Morin, MJ, 1995. DNA vaccines: a new approach to immunization. In: Brown F, Chanock R, Ginsberg H (Eds.), Vaccines 1995. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, pp. 69-75.
6. Ulmer J.B., Donnelly J.J., Parker S.E.et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science. 259:1993;1745-1749.
7. Webster R.G., Fynan E.F., Santoro J.C., Robinson H. Protection of ferrets against influenza challenge with a DNA vaccine to the hemagglutinin. Vaccine. 12:1994;1495-1504.
8. Fuller D.H., Haynes J.R. A qualitative progression in HIV type I glycoprotein 120-specific cytotoxic cellular and humoral immune response in mice receiving a DNA based glycoprotein 120 vaccine. AIDS Res. Human Retroviruses. 10:1994;1433-1441.
9. Lu S., Santoro J.C., Fuller D.H., Haynes J.R., Robinson H.L. Use of DNAs expressing HIV-1 Env and noninfectious HIV-1 particles to raise antibody responses in mice. Virology. 209:1995;147-154.
10. Lu S., Arthos J., Montefiori D.C.et al. Simian immunodeficiency virus DNA vaccine trial in macaques. Journal of Virology. 70:1996;3978-3991.
11. Xiang Z.Q., Spitalnik S., Tran M., Wunner W.H., Cheng J., Ertl H.C.J. Vaccination with a plasmid vector carrying the rabies virus glycoprotein gene induces protective immunity against rabies virus. Virology. 199:1994;132-140.
12. Davis H.L., Schirmbeck R., Reimann J., Whalen R.G. DNA-mediated immunization in mice induces a potent MHC class I-restricted cytotoxic T lymphocyte response to the hepatitis B envelope protein. Human Gene Therapy. 6:1995;1446-1456.
13. b mice. J. Immunol. 156:1996;3687-3695.
14. Michel M.-L., Davis H.L., Schleef M., Mancini M., Tiollais P., Whalen R.G. DNA-mediated immunization to the hepatitis B surface antigen in mice: aspects of the humoral response mimic hepatitis B viral infection in humans. Proc. Natl. Acad. Sci. USA. 92:1995;5307-5311.
15. Schirmbeck R., Böhm W., Ando K., Chisari F.V., Reimann J. Nucleic acid vaccination primes hepatitis B virus surface antigen-specific cytotoxic T lymphocytes in nonresponder mice. J. Virol. 69:1995;5929-5934.
16. Major M.E., Vitvitski L., Mink M.A.et al. DNA-based immunization with chimeric vectors for the induction of immune responses against the hepatitis C virus nucleocapsid. J. Virol. 69:1995;5798-5805.
17. Martins L.P., Lau L.L., Asano M.S., Ahmed R. DNA vaccination against persistent viral infection. J. Virol. 69:1995;2574-2582.
18. Yokoyama M., Zhang J., Whitton L. DNA immunization confers protection against lethal lymphocytic choriomeningitis virus infection. J. Virol. 69:1995;2684-2688.
19. Zarozinski C.C., Fynan E.F., Selin L.K., Robinson H.L., Welsy R.M. Protective CTL-dependent immunity and enhanced immunopathology in mice immunized by particle bombardment with DNA encoding an internal virion protein. J. Immunol. 154:1995;4010-4017.
20. Bourne N., Stanberry L.R., Bernstein D.I., Lew D. DNA immunization against experimental genital herpes simplex virus infection. J. Infect. Dis. 173:1996;800-807.
21. Cox G.J.M., Zamb T.J., Babiuk L.A. Bovine herpesvirus 1: immune responses in mice and cattle injected with plasmid DNA. J. Virol. 67:1993;5664-5667.
22. + T lymphocytes. J. Immunol. 155:1995;259-265.
23. McClements W.L., Armstrong M.E., Keys R.D., Liu M.A. Immunization with DNA vaccines encoding glycoprotein D or glycoprotein B, alone or in combination, induces protective immunity in animal models of herpes simplex virus-2 disease. Proc. Natl. Acad. Sci. USA. 93:1996;11414-11420.
24. González Armas J.C., Morello C.S., Cranmer L.D., Spector D.H. DNA immunization confers protection against murine cytomegalovirus infection. J. Virol. 70:1996;7921-7928.
25. Britt WJ, Alford CA, 1996. Cytomegalovirus. In: Fields, B., Knipe, N., Howley, D.M.P.M. et al. (Eds.), Virology. Lippincott-Raven, Philadelphia, PA, pp. 2493-2523.
26. Melnick J.L., Adam E., DeBakey M.E. Cytomegalovirus and atherosclerosis. BioEssays. 17:1995;899-903.
27. Berencsi K, Endresz V, Klurfeld D, Kari L, Kritchevsky D, Gönczöl E, 1997. Early atherosclerotic lesions in the aortic wall of the mouse induced by cytomegalovirus infection. Cell Adhesion Commun., in press.
28. Speir E., Modali R., Huang E.-S.et al. Potential role of human cytomegalovirus and p53 interaction in coronary restenosis. Science. 265:1994;391-394.
29. Zhou Y.F., Leon M.B., Waclawiw M.A.et al. Association between prior cytomegalovirus infection and the risk of restenosis after coronary atherectomy. N. Engl. J. Med. 335:1996;624-630.
30. Chee M.S., Bankier A.T., Beck S.et al. Analysis of the protein coding content of the sequence of human cytomegalovirus strain AD169. Curr. Topics Microbiol. Immunol. 154:1990;125-169.
31. Britt W.J., Vugler L., Butfiloski E.J., Stephens E.B. Cell surface expression of human cytomegalovirus (HCMV) gp55-116 (gB): use of HCMV-recombinant vaccinia virus-infected cells in analysis of human neutralizing antibody response. J. Virol. 64:1990;1079-1085.
32. Gönczöl E., Ianocone J., Ho W-Z., Starr S., Meigneir B., Plotkin S.A. Isolated gA/gB glycoprotein complex of human cytomegalovirus envelope induces humoral and cellular immune responses in human volunteers. Vaccine. 8:1990;130-136.
33. Marshall G.S., Rabalais G.P., Stout G.G., Waldeyer S.L. Antibodies to recombinant-derived glycoprotein B after natural human cytomegalovirus infection correlate with neutralizing activity. J. Infect. Dis. 165:1992;381-384.
34. + virus-specific cytotoxic T lymphocytes. J. Med. Virol. 43:1994;103-110.
35. Reusser P., Riddell S.R., Meyers J.D., Greenberg P.D. Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease. Blood. 78:1991;1373-1380.
36. Riddell S.R., Rabin M., Geballe A.P., Britt W.J., Greenberg P.D. Class I MHC-restricted cytotoxic T lymphocyte recognition of cells infected with human cytomegalovirus does not require endogenous viral gene expression. J. Immunol. 146:1991;2795-2804.
37. Wills M.R., Carmichael A.J., Mynard K.et al. The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL. J. Virol. 70:1996;7569-7579.
38. Marshall G.S., Ricciardi R.P., Rando R.F.et al. An adenovirus recombinant that expresses the human cytomegalovirus major envelope glycoprotein and induces neutralizing antibodies. J. Infect. Dis. 162:1990;1177-1181.
39. Gönczöl E., deTaisne C., Hirka G.et al. High expression of human cytomegalovirus (HCMV)-gB protein in cells infected with a vaccinia-gB recombinant; the importance of the gB protein in HCMV-immunity. Vaccine. 9:1991;631-637.
40. Gönczöl E., Berencsi K., Pincus S.et al. Preclinical evaluation of an ALVAC (canarypox)-human cytomegalovirus glycoprotein B vaccine candidate. Vaccine. 13:1995;1080-1085.
41. Berencsi K, Gönczöl E, Valyi-Nagy T, et al., 1991. Recombinant human cytomegalovirus (HCMV)-gB glycoprotein induces gB-specific cell-mediated immunity in mice. In: Landini MP (Ed.), Progress in Cytomegalovirus Research, Excerpta Medica Proceedings of the 3rd International Cytomegalovirus Workshop, pp. 191-194.
42. Berencsi K., Rando R., deTaisne C., Paoletti E., Plotkin S.A., Gönczöl E. Murine cytotoxic T cell response specific for human cytomegalovirus glycoprotein B (gB) induced by adenovirus and vaccinia virus recombinants expressing gB. J. Gen. Virol. 74:1993;2507-2512.
43. Gossen M., Bujard H. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc. Natl. Acad. Sci. USA. 89:1992;5547-5551.
44. Gönczöl E., Furlini G., Ianacone J., Plotkin S.A. A rapid microneutralization assay for cytomegalovirus. J. Virol. Methods. 14:1986;37-41.
45. Gönczöl E., Berencsi K., Kauffman E.et al. Preclinical evaluation of an ALVAC (canarypox)-human cytomegalovirus glycoprotein B vaccine candidate: immune response elicited in a prime/boost protocol with the glycoprotein B subunit. Scand. J. Infect. Dis. (Suppl.). 99:1995;110-112.
46. Hocart M.J., Mackenzie J.S., Stewart G.A. The IgG subclass responses to influenza virus haemagglutinin in the mouse: effect of route of inoculation. J. Gen. Virol. 70:1989;809-818.
47. Banks T., Huo B., Kousoulas K., Spaete R., Pachl C., Pereira L. A major neutralizing domain maps within the carboxyl-terminal half of the cleaved cytomegalovirus B glycoprotein. J. Gen. Virol. 70:1989;979-985.
48. Spaete R.R., Gehrz R.C., Landini M.P. Human cytomegalovirus structural proteins. J. Gen. Virol. 75:1994;3287-3308.
49. Donnelly J.J., Ulmer J.B., Shiver J.W., Liu M.A. DNA vaccines. Annu. Rev. Immunol. 15:1997;617-618.
50. Raz E., Tighe H., Sato Y.et al. Preferential induction of a Th1 immune response and inhibition of specific IgE antibody formation by plasmid DNA immunization. Proc. Natl. Acad. Sci. USA. 93:1996;5141-5145.
51. Feltquate D.M., Heaney S., Webster R.G., Robinson H.L. Different T helper cell types and antibody isotypes generated by saline and gene gun DNA immunization. J. Immunol. 158:1997;2278-2284.
52. Urban M., Winkler T., Landini M.P., Britt W., Mach M. Epitope-specific distribution of IgG subclasses against antigenic domains on glycoproteins of human cytomegalovirus. J. Infect. Dis. 169:1994;83-90.
53. Tomiyama T., Matsumoto Y.-I., Sugano T., Fujinaga S., Masuho Y. Preparation of human monoclonal antibodies against a cytomegalovirus glycoprotein complex of 130 and 55 kDa. J. Immunol. Meth. 131:1990;249-255.
54. Britt W., Fay J., Seals J., Kensil C. Formulation of an immunogenic human cytomegalovirus vaccine: responses in mice. J. Infect. Dis. 171:1995;18-25.
55. Lussenhop N.O., Goertz R., Wabuke-Bunoti M., Gehrz R., Kari B. Epitope analysis of human cytomegalovirus glycoprotein complexes using murine monoclonal antibodies. Virology. 164:1988;362-372.
56. Rasmussen L., Mullenax J., Nelson R., Merigan T.C. Viral polypeptides detected by a complement-dependent neutralizing murine monoclonal antibody to human cytomegalovirus. J. Virol. 55:1985;274-280.
57. Britt W.J. Neutralizing antibodies detect a disulfide-linked glycoprotein complex within the envelope of human cytomegalovirus. Virology. 135:1984;369-378.
58. Pande H., Campo K., Tanamachi B., Forman S.J., Zaia J.A. Direct DNA immunization of mice with plasmid DNA encoding the tegument protein pp65 (ppUL83) of human cytomegalovirus induces high levels of circulating antibody to the encoded protein. Scand. J. Infect. Dis. 99:1995;117-120.
59. Yankauckas M.A., Morrow J.E., Parker S.E.et al. Long-term anti-nucleoprotein cellular and humoral immunity is induced by intramuscular injection of plasmid DNA containing NP gene. DNA Cell Biol. 12:1993;771-776.
60. Mor G., Klinman D.M., Shapiro S.et al. Complexity of the cytokine and antibody response elicited by immunizing mice with Plasmodium yoelii circumsporozoite protein plasmid DNA. J. Immunol. 155:1995;2039-2046.